{"id":"NCT00595517","sponsor":"AstraZeneca","briefTitle":"Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-induced Ulcer","officialTitle":"A Long Term Study to Investigate the Efficacy and Safety Study of D961H (Esomeprazole) (20 mg Once Daily) for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-inflammatory Drug (NSAID) Use","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-10","primaryCompletion":"2009-09","completion":"2009-09","firstPosted":"2008-01-16","resultsPosted":"2012-09-14","lastUpdate":"2012-09-14"},"enrollment":395,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Gastric Ulcer","Duodenal Ulcer","Rheumatoid Arthritis","Osteoarthritis","Lumbago"],"interventions":[{"type":"DRUG","name":"Esomeprazole 20 mg","otherNames":[]}],"arms":[{"label":"Esomeprazole 20 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the Safety and tolerability of D961H (Esomeprazole) 20 mg once daily for up to 52 weeks of treatment involving patients with a history of gastric and/or duodenal ulcers receiving daily nonsteroidal anti-inflammatory drug (NSAID) therapy by evaluating AE, clinical laboratory value and vital signs.","primaryOutcome":{"measure":"Number of Participants Without Gastric and/or Duodenal Ulcer Throughout the Treatment Period","timeFrame":"up to 52 weeks","effectByArm":[{"arm":"Esomeprazole 20mg","deltaMin":125,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":3,"countries":["Japan"]},"refs":{"pmids":["23530709"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":130},"commonTop":["Nasopharyngitis","Rheumatoid Arthritis","Abdominal Pain Upper","Constipation","Diarrhoea"]}}